No abstract

Six new anionic bismuth-oxido clusters containing trifluoroacetate ligands were prepared. These include two new BiO clusters: [M(NCMe)(HO)][Bi(μ-O)(μ-OH)(CFCO)] with an octahedral BiO(OH) core (M = Ni, 1a; Co, 1b) and four BiO clusters, {[Co(NCMe)][Bi(μ-O)(CFCO)]} (2a), {[Co{HC(MeCO)(MeCNH)}][Bi(μ-O)(CFCO)]·2[CFCO]·2[CFCOH]·2[HO]} (2b), {[Cu(NCMe)][Bi(μ-O)(CFCO)]·2[CFCOH]} (2c), and {[MeN][Bi(μ-O)(CFCO)]·2[CFCOH]} (2d). These are among the first bismuth-oxido anionic clusters synthesized, and the first to have transition metal countercations. The BiO anion in 1a and 1b is a high-symmetry octahedron. Additionally, two of the new BiO clusters are arranged in 1D polymeric structures via bridging carboxylate ligands. The cation in compound 2c had not been previously characterized and was also observed in the synthesis of [Co{HC(MeCO)(MeCNH)}][Bi(NO)] (3). The new compounds were characterized using single crystal X-ray crystallography and elemental analysis.

A series of substituted dihydropyrimidin-2(1H)-thione derivatives (1–8) have been synthesized and docked against enzymes human topoisomerase II alpha (4FM9) and Helicobacter pylori urease (1E9Y) for binding mode validation.

Five new carboxylic acid precursors bearing thiourea group and their corresponding bismuth(III) complexes were synthesized and characterized using CHNS and inductively coupled plasma analyses and infrared and NMR ( 1 H, 13 C) spectroscopies. Single-crystal X-ray diffraction analysis was also carried out for one of the precursors. The behaviour of the compounds was bioassayed for antibacterial, antifungal, antioxidant and enzyme (lipoxygenase, α-glycosidase and anti-urease) inhibition activities. It is concluded that the interaction of the compounds with bismuth enhances both the antimicrobial and enzyme inhibition activities. The synthesized compounds may prove to be good therapeutic agents.

No abstract